If you have questions, please call us for more information about clinical trials or use our online form.
- Cancer clinical trials: 414-805-8900
- Noncancer clinical trials: 414-955-8555
Learn more about clinical trials basics and early-phase clinical trials, as well as some of the unique features our research program, including our Translational Research Unit. Froedtert & MCW health network is also part of the National Institutes of Health All of Us Research Program.
Displaying 1 - 10 of 45
A Phase II Study of the Efficacy and Pharmacogenomics of Cladribine-Based Salvage Chemotherapy in Patients with Relapse/Refractory and Secondary Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)
Objective
Efficacy and Pharmacogenomics of Salvage CLAG-M Chemotherapy in Patients With Relapse/Refractory and Secondary Acute Myeloid Leukemia
Protocol No
IIT-ATALLAH-CLAGM-AML
Categories
Master Protocol for the Phase 1 Study of Cell Therapies for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma, Including Long-Term Safety Follow-Up
Objective
Master Protocol for the Phase 1 Study of Cell Therapies in Multiple Myeloma
Protocol No
ARCELLX-ACLX-001-DDBCMA
Categories
A Multisite, Phase II Study of Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
Objective
Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory MM
Protocol No
IIT-DHAKAL-IMPEDE-SGZ-12356
Categories
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417 as Monotherapy, in Combination With Dexamethasone, Dexamethasone/Carfilzomib, Dexamethasone/Daratumumab, and Dexamethasone/Pomalidomide in Patie
Objective
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to
Determine the Safety and Efficacy of BGB-11417 in Combination With Dexamethasone andCarfilzomib/Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14)
Determine the Safety and Efficacy of BGB-11417 in Combination With Dexamethasone andCarfilzomib/Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14)
Protocol No
BEIGENE-BGB-11417-105
A Phase III Randomized Trial of Steroids + Tyrosine Kinase Inhibitor (TKI) Induction with Chemotherapy or Blinatumomab for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia (ALL) in Adults
Objective
Steroids plus TKI with Blinatumomab or Chemo for Newly Diagnosed BCR-ABL Positive ALL in Adults
Protocol No
ECOG-EA9181-ALL
Categories
A Phase 1, Multicenter, Open-Label Study of CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma
Objective
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell NHL
Protocol No
CARIBOU-CB10A-ANTLER-NHL
Categories
A Phase 1b Study of Oral AS-1763 in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non Hodgkin Lymphoma
Objective
A Phase 1b Study of Oral AS-1763 in Patients with CLL/SLL or NHL
Protocol No
CARNABIOSCIENCES-C1763102
Categories
A Phase II Trial of De-Escalated PTCy and Ruxolitinib for GVHD Prophylaxis in Patients Undergoing Reduced Intensity Conditioning Allogeneic HCT
Objective
A Phase 2 Trial of PTCy and Ruxolitinib for GVHD Prophylaxis in Patients Undergoing Allogenic HCT
Protocol No
IIT-ABEDIN-PTCY-RUX-GVHD
Categories
A Multicenter, Randomized, Open-Label, Blinded Endpoint Evaluation, Phase 3 Study Comparing the Effect of Abelacimab Relative to Apixaban on Venous Thromboembolism (VTE) Recurrence and Bleeding in Patients with Cancer Associated VTE
Objective
A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE (ASTER)
Protocol No
ANTHOS-ANT-007
Categories
Cancer,
Eye/Orbital Cancers,
Skin Cancers,
Cervix,
Lip, Oral Cavity and Pharynx,
Sarcoma,
Other Gastrointestinal,
Other Blood Related,
Pancreas/Liver,
Uterine,
Other Respiratory,
Gynecologic Cancers,
Brain and Spine Cancers,
Bladder,
Lung,
Head and Neck Cancers,
Leukemia,
Prostate,
Esophagus,
Thoracic Cancers,
Colorectal,
Hematologic/Blood Related Cancers,
Gastrointestinal Cancers,
Kidney,
Endocrine Cancers,
Prostate and Urologic Cancers,
Multiple Myeloma,
Breast Cancers
A Randomized Phase II Study Comparing Inotuzumab Plus Chemotherapy Versus Standard Chemotherapy in Older Adults with Philadelphia-Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia
Objective
This study is being done to answer the following question: Can we improve the chance of your leukemia going away (remission) and lower the chance of your leukemia coming back (relapsing) by adding an investigational drug called inotuzumab ozogamicin (hereafter, inotuzumab) to lower doses of the usual chemotherapy for acute lymphoblastic leukemia?
We are doing this study because we want to find out if this approach is better or worse than the
usual approach for your acute lymphoblastic leukemia. The usual approach is defined as care
most people get for acute lymphoblastic leukemia.
We are doing this study because we want to find out if this approach is better or worse than the
usual approach for your acute lymphoblastic leukemia. The usual approach is defined as care
most people get for acute lymphoblastic leukemia.
Protocol No
ALLIANCE-A042001
Categories